BioNTech SE (BNTX) Misses Q2 EPS by 134c, reiterates guidance

BioNTech SE (NASDAQ: BNTX) reported Q2 EPS of (EUR3.36), EUR1.34 worse than the analyst estimate of (EUR2.02). Revenue for the quarter came in at EUR128.7 million versus the consensus estimate of EUR134.98 million.

GUIDANCE:

BioNTech SE sees FY2024 revenue of EUR2.5-3.1 billion, versus the consensus of EUR3.002 billion.

For earnings history and earnings-related data on BioNTech SE (BNTX) click here.

You May Also Be Interested In

• Ennis (EBF) Reports In-Line Q1 EPS
• Seer and Korea University share early cancer screening proteomics data
• TDAC shareholders vote to extend SPAC, keeping $156.8M in trust